Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23724Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Rizos, C. V. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.date.accessioned | 2015-11-24T19:35:40Z | - |
| dc.date.available | 2015-11-24T19:35:40Z | - |
| dc.identifier.issn | 1873-4286 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23724 | - |
| dc.rights | Default Licence | - |
| dc.subject | Angiotensin II Type 1 Receptor Blockers/*pharmacology/therapeutic use | en |
| dc.subject | Benzimidazoles/*pharmacology/therapeutic use | en |
| dc.subject | Benzoates/*pharmacology/therapeutic use | en |
| dc.subject | Body Fat Distribution | en |
| dc.subject | Cholesterol, LDL/blood | en |
| dc.subject | Clinical Trials as Topic | en |
| dc.subject | Diabetes Mellitus, Type 2/drug therapy | en |
| dc.subject | Glucose/metabolism | en |
| dc.subject | Heart Failure/drug therapy | en |
| dc.subject | Humans | en |
| dc.subject | Hypertension/complications/*drug therapy | en |
| dc.subject | Hypertrophy, Left Ventricular/prevention & control | en |
| dc.subject | Insulin Resistance | en |
| dc.subject | Kidney/drug effects/physiopathology | en |
| dc.subject | PPAR gamma/physiology | en |
| dc.subject | Randomized Controlled Trials as Topic | en |
| dc.title | Are the pleiotropic effects of telmisartan clinically relevant? | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/19689352 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2009 | - |
| heal.abstract | Hypertension is one of the major risk factors for cardiovascular disease. Angiotensin receptor blockers (ARBs) are a class of antihypertensive drugs with established efficacy and favorable safety profile. Telmisartan, a member of the ARB family, holds some additional traits which differentiate it from the rest ARBs. A pivotal role in these characteristics plays its ability to partially activate the peroxisome proliferator activated receptor-gamma, which in turn controls a number of metabolism-related genes. Indeed, telmisartan has shown a number of pleiotropic effects in experimental and clinical studies. These include the amelioration of insulin resistance, improvement of lipid profile and favorable fat redistribution. Moreover, telmisartan has been associated with beneficial effects on vascular function, cardiac remodeling and renal function. However, do all these pleiotropic effects translate into clinical benefit? Recent studies have tried to answer this question with promising but not definitive results. | en |
| heal.journalName | Curr Pharm Des | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
